All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What are the critical issues that need to be addressed to achieve outpatient administration of CAR T-cell therapy?
What are the critical issues to address for outpatient administration of CAR T-cell therapy?
Ulrich Jäger discusses this question with reference to the OUTREACH trial and the importance of patient selection.
Prof. Ulrich Jager | ASH 2017 | Personalisation in DLBCL
59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Ulrich Jager Medical University of Vienna, Vienna, AT Topic: Personalisation in DLBCL
Will CAR T-cell therapy change the treatment landscape for MCL?
During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Marion Subklewe, Ludwig-Maximilians-Universität München, Munich, DE. We asked, Will CAR T-cell therapy change the...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox